COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Immunobridging trials: Bringing medicines to patients faster
Virology Research Clinic - University of Washington
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | NEJM
Virology Research Clinic - University of Washington
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Participants sought for COVID-19 vaccine trial for booster and variant protection
UC Davis and Pfizer partner on two new COVID-19 booster vaccine clinical trials
GCT to Perform Booster Visits in Russia
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
Coronavirus information
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
FDA will not require clinical trial data to authorize redesigned COVID boosters -official | Reuters
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial - eBioMedicine
COVID-19 Boosters: Why You Should Schedule One Now
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
COVID-19 Booster Vaccine Study | Suburban Hospital | Johns Hopkins Medicine
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years | NEJM
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins | National Institutes of Health (NIH)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
